Clinical trial
Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma
NCT00306618 · CASI Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00306618 |
|---|---|
| Title | Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma |
| Official title | A Single-Center, Open-Label, Phase II, Safety, Pharmacokinetic and Efficacy of Panzem Nanocrystal Colloidal Dispersion Administered Orally to Patients With Recurrent Glioblastoma Multiforme |
| Lead sponsor | CASI Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Glioblastoma Multiforme |
| Intervention type | Drug |
| Interventions | Panzem Nanocrystal Colloidal Dispersion |
| Enrollment | 27 |
| Start date | Jan 1, 2006 |
| Primary completion | Nov 1, 2007 |
| Completion | Dec 1, 2008 |
| First posted | Mar 24, 2006 |
| Last update posted | Dec 10, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: